EA200802381A1 - Лечение желудочно-кишечных расстройств антагонистами cgrp-пептида - Google Patents

Лечение желудочно-кишечных расстройств антагонистами cgrp-пептида

Info

Publication number
EA200802381A1
EA200802381A1 EA200802381A EA200802381A EA200802381A1 EA 200802381 A1 EA200802381 A1 EA 200802381A1 EA 200802381 A EA200802381 A EA 200802381A EA 200802381 A EA200802381 A EA 200802381A EA 200802381 A1 EA200802381 A1 EA 200802381A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
gastrointestinal disorders
cgrp
peptide
antagonists
Prior art date
Application number
EA200802381A
Other languages
English (en)
Inventor
Хенри Додс
Кирстен Арндт
Тьерри Буиссу
Штефан Георг Мюллер
Клаус Рудольф
Герхард Шэнцле
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200802381(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA200802381A1 publication Critical patent/EA200802381A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке описан способ предупреждения и лечения висцеральной боли и желудочно-кишечных расстройств, таких как нарушения функции кишечника и воспалительные заболевания кишечника, основанный на применении в эффективных количествах соединения, обладающего действием антагониста CGRP-пептида.
EA200802381A 2006-06-08 2007-06-06 Лечение желудочно-кишечных расстройств антагонистами cgrp-пептида EA200802381A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06011787 2006-06-08
PCT/EP2007/055543 WO2007141285A1 (en) 2006-06-08 2007-06-06 Treatment of gastrointestinal disorders with cgrp-antagonists

Publications (1)

Publication Number Publication Date
EA200802381A1 true EA200802381A1 (ru) 2009-06-30

Family

ID=37101671

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200802381A EA200802381A1 (ru) 2006-06-08 2007-06-06 Лечение желудочно-кишечных расстройств антагонистами cgrp-пептида

Country Status (19)

Country Link
US (2) US20080139591A1 (ru)
EP (2) EP2029233A2 (ru)
JP (2) JP2009539800A (ru)
KR (1) KR20090021214A (ru)
CN (1) CN101500653A (ru)
AR (2) AR061272A1 (ru)
AU (1) AU2007255395A1 (ru)
BR (1) BRPI0712492A2 (ru)
CA (2) CA2654048A1 (ru)
CL (2) CL2007001662A1 (ru)
EA (1) EA200802381A1 (ru)
EC (1) ECSP089025A (ru)
IL (1) IL195712A0 (ru)
MX (1) MX2008015562A (ru)
NO (1) NO20085051L (ru)
PE (2) PE20080153A1 (ru)
TW (2) TW200808791A (ru)
UY (2) UY30398A1 (ru)
WO (2) WO2007141285A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007255395A1 (en) * 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Treatment of gastrointestinal disorders with CGRP-antagonists
WO2010070023A2 (en) * 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh Formulations
FR2963738B1 (fr) * 2010-08-10 2012-09-28 Assist Publ Hopitaux De Paris Compose destine au traitement des douleurs abdominales fonctionnelles
CN108424452B (zh) 2011-05-20 2021-08-03 H.伦德贝克公司 抗cgrp组合物及其用途
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
NZ717704A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
TWI636041B (zh) * 2015-08-12 2018-09-21 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5291960A (en) * 1992-11-30 1994-03-08 Ford Motor Company Hybrid electric vehicle regenerative braking energy recovery system
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) * 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2005041757A2 (en) * 2003-10-29 2005-05-12 University Of Rochester Detection of neuropeptides associated with pelvic pain disorders and uses thereof
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
EP1770091A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CN101146799A (zh) * 2005-03-23 2008-03-19 贝林格尔·英格海姆国际有限公司 Cgrp拮抗剂、其制备方法以及其作为药物的用途
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102005038831A1 (de) * 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770087A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
AU2007255395A1 (en) * 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Treatment of gastrointestinal disorders with CGRP-antagonists

Also Published As

Publication number Publication date
AR061271A1 (es) 2008-08-13
KR20090021214A (ko) 2009-02-27
UY30398A1 (es) 2008-01-31
WO2007141284A2 (en) 2007-12-13
US20080139537A1 (en) 2008-06-12
EP2029233A2 (en) 2009-03-04
CL2007001663A1 (es) 2008-01-25
JP2009539800A (ja) 2009-11-19
CA2654047A1 (en) 2007-12-13
TW200808791A (en) 2008-02-16
AU2007255395A1 (en) 2007-12-13
US20080139591A1 (en) 2008-06-12
PE20080370A1 (es) 2008-06-13
TW200815010A (en) 2008-04-01
PE20080153A1 (es) 2008-04-14
CA2654048A1 (en) 2007-12-13
CL2007001662A1 (es) 2008-01-25
AR061272A1 (es) 2008-08-13
ECSP089025A (es) 2009-01-30
CN101500653A (zh) 2009-08-05
NO20085051L (no) 2008-12-19
JP2009539799A (ja) 2009-11-19
BRPI0712492A2 (pt) 2012-08-21
US7807666B2 (en) 2010-10-05
UY30399A1 (es) 2008-01-31
WO2007141285A1 (en) 2007-12-13
MX2008015562A (es) 2008-12-17
IL195712A0 (en) 2009-09-01
WO2007141284A3 (en) 2008-03-06
EP2029234A1 (en) 2009-03-04

Similar Documents

Publication Publication Date Title
EA200802381A1 (ru) Лечение желудочно-кишечных расстройств антагонистами cgrp-пептида
EA200870409A1 (ru) Антагонисты киназы pi3
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
ATE469895T1 (de) Cgrp-rezeptorantagonisten
EA200870385A1 (ru) Ингибирование токсичности альфа-синуклеина
BRPI0605921A2 (pt) compostos orgánicos
WO2007109456A3 (en) Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists
LTC1776142I2 (lt) IL-17 antagonistiniai antikūnai
ATE477252T1 (de) Substituierte diazepane als antagonisten an orexinrezeptoren
EA200702568A1 (ru) Гетеробициклические ингибиторы металлопротеазы и их применение
ATE414074T1 (de) 2-oxo-1,2,4,5-tetrahydro-1,3-benzdiazepin-3-yl- piperidine als cgrp-antagonisten
EA200970459A1 (ru) Лекарственные формы и совместное введение опиоидного агониста и опиоидного антагониста
WO2005072308A3 (en) Cgrp receptor antagonists
WO2008064321A3 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
DK1706112T3 (da) Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
EA200870292A1 (ru) Соединения на основе имидазола, композиции, содержащие их, и способы их применения
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
ATE484505T1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
RS51069B (sr) Upotreba oksikodona za tretiranje visceralnog bola
TW200744584A (en) Use of mGluR5 antagonists (ESP. AFQ056) in GI (ESP. GERD)
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
WO2010077976A3 (en) Prokineticin receptor antagonists and uses thereof